Description: Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116. The company was incorporated in 2010 and is based in Umeå, Sweden.
Home Page: www.lipum.se
TvistevAegen 48C
Umeå,
907 36
Sweden
Phone:
46 9 03 40 34 30
Officers
| Name | Title |
|---|---|
| Dr. Einar Ponten | Chief Exec. Officer |
| Associate Prof. Susanne Lindquist | Co-Founder & Head of Research (CSO) |
| Prof. Olle Hernell | Co-Founder & Director |
| Ms. Marina Norberg | Chief Financial Officer |
| Dr. Pernilla Abrahamsson | Chief Operating Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 35.6459 |
| Price-to-Sales TTM: | 3380.242 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |